

23. (Original) In a method for treatment of an individual with a disorder including repetitive behaviors, social deficits and cognitive deficits, by administration of psychopharmacologic agents, the improvement comprising: additional administration of a therapeutically effective amount of a composition comprising oxytocin, oxytocin analog or combination thereof.
24. (Previously Amended) The method of claim 23 wherein said oxytocin is an oxytocin analog selected from the group consisting of 4-threonine-1-hydroxy-deaminoxytocin, 9-deamidooxytocin, 7-D-proline-oxytocin and its deamino analog, (2,4-diisoleucine)-oxytocin, deamino oxytocin analog, 1-deamino-1-monocarba-E12-[Tyr (OMe)]-OT(dCOMOT), carbetocin, Ile-conopressin, atosiban, [Thr4-Gly7]-oxytocin, oxypressin, deamino-6-carba-oxytocin (dC60), d[Lys(8)(5/6C-Flu)]VT, d[Thr(4),Lys(8)(5/6C-Flu)]VT, [HO(1)][Lys(8)(5/6C-Flu)]VT, [HO(1)][Thr(4),Lys(8)(5/6C-Flu)]VT, d[Orn(8)(5/6C-Flu)]VT, d[Thr(4),Orn(8)(5/6C-Flu)]VT, [HO(1)][Orn(8)(5/6C-Flu)]VT, [HO(1)][Thr(4),Orn(8)(5/6C-Flu)]VT and oxytocin fragments.
25. (Original) The method of claim 23, wherein said psychopharmacologic agent is selected from the group consisting of sedatives, tranquilizers, antipsychotics, antidepressants and anticonvulsants.
26. (Original) The method of claim 23, wherein said psychopharmacologic agent affects the opiate, noradrenergic, dopaminergic, serotonergic, glutamatergic and GABAergic systems.
27. (Previously Amended) The method of claim 23 wherein said therapeutically effective amount is 10 units per ml oxytocin dissolved into 1000 mL normal saline, administered at a rate of 10 milliunits per minute or 6 units/hour.
28. (Original) The method of claim 23 wherein said composition is oxytocin.

29. (Cancelled)
30. (Previously Amended) The method of claim 23, wherein said disorder including social deficits is Social Anxiety Disorder.
31. (Cancelled)